ReviewThe Lancet regional health. Western Pacific2025
What is the role of common sense oncology in the Western Pacific?
Review in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards equitable cancer outcomes for rural and remote communities: reflections, lessons and recommendations.The Lancet regional health. Western Pacific · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Established in 2023, Common Sense Oncology (CSO) is a grass roots initiative uniting cancer clinicians, policymakers, academics, patients and their advocates that calls for a 'recalibration' of cancer care to focus on outcomes that matter to patients. CSO emphasises treatments that substantially improve survival and quality of life, and advocates for equitable global access to effective cancer therapies. This article examines the potential of CSO principles to improve cancer care in the Western Pacific, a geographically and culturally diverse region that shoulders one-third of the global cancer burden. We review early progress of CSO working groups and identify regional challenges, such as engaging diverse membership, fostering local change, and evaluating impact. Unique regional strengths, such as longstanding cooperative trial group and China's growing influence in global drug development, are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.